Brief: Inhibikase Therapeutics To Present Data From Phase 1/1B Study Of IkT-148009 At The Movement Disorders Society Congress
15/09/2022 13:37
Sept 15 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS TO PRESENT DATA FROM PHASE 1/1B
STUDY OF
IKT-148009 AT THE MOVEMENT DISORDERS SOCIETY CONGRESS
* INHIBIKASE THERAPEUTICS INC - NO CLINICALLY SIGNIFICANT
ADVERSE
EVENTS OBSERVED
* INHIBIKASE THERAPEUTICS INC - ACTIVELY ENROLLING PHASE 2A
'201'
CLINICAL TRIAL OF IKT-148009 IN PATIENTS WITH UNTREATED
PARKINSON'S DISEASE
* INHIBIKASE - IKT-148009 WAS WELL-TOLERATED WITH HIGH
SYSTEMIC
EXPOSURE, PERSISTENT PENETRATION INTO CNS IN OLDER, ELDERLY
HEALTHY VOLUNTEERS, PARKINSON'S PATIENTS
Source text for Eikon: ID:nPn1vtc9qa
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary